This site is for U.S. Healthcare Professionals Only
This site is for U.S. Healthcare Professionals Only
This site is for U.S. Healthcare Professionals Only
This site is for U.S. Healthcare Professionals Only
FDA-approved oral solution of metoprolol tartrate
that is safe, effective, and convenient
Transforming treatment with a ready-to-administer
liquid formulation
Calibrated oral dosing syringe is included for
personalized treatment to meet each patient’s needs
The liquid formulation enables titration, offering
greater flexibility in dosing adjustments
The oral solution supports a gradual
reduction in dose
Discover the liquid innovation that offers treatment for adults with hypertension, angina pectoris and hemodynamically stable patients with definite or suspected myocardial infarction in an easy-to-swallow oral solution.
Liquid formulation for established efficacy and easier dosing!
Calibrated oral dosing syringe features clear dose indicators for ease of titration
Ready-to-use solution and a calibrated oral dosing syringe for personalized care
The oral solution supports a gradual reduction in dose
Lopressor® is indicated for the treatment of adults with hypertension, angina pectoris and hemodynamically stable patients with definite or suspected myocardial infarction.
Please click here for full Prescribing Information.
Lopressor® Oral Solution is the First and Only FDA-Approved Oral Liquid Metoprolol Tartrate that is a safe and effective option to treat patients with hypertension, angina pectoris and hemodynamically stable patients with definite or suspected myocardial infarction.1
A convenient metoprolol tartrate
oral solution for flexibility and
ease of administration
Liquid dosing makes Lopressor® Oral Solution an ideal choice to reduce caregiver burden
Provides an alternative for patients who find it challenging to take tablets or capsules
Stable at controlled room temperature (20°C to 25°C/ 68°F to 77°F) and does not require refrigeration
Liquid formulation eliminates the need to split or dissolve tablets for hassle-free dosing
Neutral taste, making it a palatable solution for patients
A convenient metoprolol tartrate oral solution for flexibility and ease of administration
Liquid dosing makes Lopressor® Oral Solution an ideal choice to reduce caregiver burden
Provides an alternative for patients who find it challenging to take tablets or capsules
Stable at controlled room temperature (20°C to 25°C/ 68°F to 77°F) and does not require refrigeration
Liquid formulation eliminates the need to split or dissolve tablets for hassle-free dosing
Neutral taste, making it a palatable solution for patients
Not actual product size.
FDA-approved medications versus compounded drugs: the key differences
Unlike some compounded drugs, Lopressor® Oral Solution
• Meets standards for potency and purity*
• Includes FDA-approved labeling
• Complies with the FDA’s Current Good Manufacturing Practices*
• Uses an active ingredient sourced and approved by the FDA
*Not all compounders are registered with the FDA; therefore, compounding is dependent on whether the product is compounded at a facility that meets the conditions of section 503A of the Food, Drug, and Cosmetic Act
or an outsourcing facility.
• No Crushing
• No Compounding
• No Mixing
• No Guesswork
• Up to 34% of FDA-tested compounded drugs failed
quality standards, including potency testing2
• Compounded medications are not FDA-approved,
leaving safety and efficacy unverified3
Lopressor® Oral Solution, 10 mg/mL, comes in bottle with a child-resistant cap, a bottle adapter, and a 10 mL calibrated oral dosing syringe, allowing patients or caregivers to conveniently prepare and take the measured dose. The calibrated oral dosing syringe features clear dose indicators for ease of titration.
Lopressor® Oral Solution is available as1:
White, opaque, high-density
polyethylene (HDPE) bottle
Starting dosage is 100 mg orally daily in single or divided doses; may be adjusted at weekly intervals up to a maximum of 450 mg per day
Start with 100 mg daily in two divided doses; gradually increase weekly to a maximum of 400 mg per day
Begin with 50 mg every 6 hours for 48 hours post-IV metoprolol, then titrate to a maintenance dose of 100 mg twice daily
Lopressor® Oral Solution Dose Conversion Calculator
Convert Lopressor® Oral Solution dose from mg to mL with precision
Read the Instructions for Use before
you start taking Lopressor® Oral Solution
for the first time and each time you get
a refill since there may be new information.
This information does not take the place of
talking to your healthcare provider
about your medical condition or
treatment.
Please click here for full Prescribing
Information.
Not Actual Product Size
Actor Potrayal
Lopressor® Oral Solution has well established safety and tolerability profile. Most common adverse reactions tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash.
Please click here for full Prescribing Information.
Lopressor® Oral Solution has well established safety
and tolerability profile. Most common adverse reactions
tiredness, dizziness, depression, shortness of breath,
bradycardia, hypotension, diarrhea, pruritus, rash.
Please click here for full Prescribing Information.
Lopressor® Liquid Innovation With CareTM Patient Support Program
Actor Potrayal
Validus is committed to improving patient access to treatment through the Lopressor® Liquid Innovation With CareTM Patient Support Program.
Designed to help patients start and stay on treatment, the program provides comprehensive support throughout their journey.
All programs are subject to change or termination without prior notice.
Once you prescribe Lopressor® (Metoprolol Tartrate) Oral Solution, your patients may enroll in the program to access benefits.
Validus is committed to improving patient
access to treatment through the Lopressor® Liquid
Innovation With CareTM Patient Support Program.
Designed to help patients start and stay on
treatment, the program provides comprehensive
support throughout their journey.
All programs are subject to change or termination
without prior notice.
Once you prescribe Lopressor® (Metoprolol
Tartrate) Oral Solution, your patients may
enroll in the program to access benefits.
The Copay Card can help eligible, commercially insured patients access their medication for as little as $10 for a 30-day supply.* Click here to download a copay card for your patients.
For more information or assistance, please contact ConnectiveRx Customer Service at 877-384-1417.
*Eligibility: Available to patients with commercial insurance coverage for Lopressor® (metoprolol tartrate) who meet eligibility criteria. This copay assistance program is not available to patients receiving
prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of
Defense, or Veterans Affairs programs) or where prohibited by law. The offer is subject to change or termination without prior notice. Restrictions, including monthly maximums, may apply.
This is not health insurance. For full Terms and Conditions, visit ConnectiveRx Customer Service at 877-384-1417 for additional information.
Our one location service provides comprehensive support in navigating patient coverage:
For assistance, please contact Reimbursement Revenue Solutions (HUB) at:
For patients whose insurers are not covering Lopressor® Oral Solution,the Program offers a straightforward, affordable option to access medication. Eligible patients can purchase Lopressor® Oral Solution, at a reduced cost through this program, ensuring uninterrupted access to their treatment.
Actor Potrayal
For uninsured patients who meet eligibility requirements, the program offers free access to medication.
For more information, contact our support team at:
1. Lopressor®. Prescribing information. Validus Pharmaceuticals; 2025.
2. Report: Limited FDA Survey of Compounded Drug Products. U.S. Food and Drug Administration. Accessed June 09, 2025. https://www.fda.gov/drugs/human-drug-compounding/report-limited-fda-survey-compounded-drug-products
3. Human Drug Compounding Laws. U.S. Food and Drug Administration. Accessed June 09, 2025. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
LOPRESSOR is a beta-adrenergic blocker indicated in adult patients:
• For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
• In the long-term treatment of angina pectoris.
• In the treatment of hemodynamically stable patients with definite or suspected myocardial infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy.
LOPRESSOR is contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, systolic blood pressure <100, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients hypersensitive to any component of this product.
Abrupt cessation of LOPRESSOR can cause exacerbations of angina pectoris and in some cases, myocardial infarction. Taper the dose over a period of 1–2 weeks and monitor closely particularly in patients with ischemic heart disease. If angina markedly worsens or acute coronary ischemia develops, promptly reinstate LOPRESSOR, and take measures appropriate for the management of unstable angina. Warn patients not to interrupt therapy without their physician’s advice. Because coronary artery disease is common and may be unrecognized, avoid abruptly discontinuing LOPRESSOR in patients treated only for hypertension.
LOPRESSOR may temporarily worsen cardiac failure during up-titration. If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of LOPRESSOR. Dose reduction or temporary discontinuation may be needed, but such episodes do not preclude subsequent successful titration of LOPRESSOR.
Patients with bronchospastic disease, in general, should not receive beta-blockers, including LOPRESSOR. Because of its relative beta1 cardio-selectivity, however, LOPRESSOR may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.
If LOPRESSOR is used in the setting of pheochromocytoma, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated.
Avoid initiation of a high-dose regimen of beta-blocker therapy in patients undergoing non-cardiac surgery, since such use in patients with cardiovascular risk factors has been associated with bradycardia, hypotension, stroke and death. Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however, the impaired ability of the heart to respond to reflex adrenergic stimuli may increase the risks of general anesthesia and surgical procedures.
Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i.e., surgery, not eating regularly, or are vomiting). If severe hypoglycemia occurs, patients should be instructed to seek emergency treatment.
Beta adrenergic blockade may mask certain clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of beta-blockade may precipitate a thyroid storm.
While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.
LOPRESSOR can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.
See Full Prescribing Information for additional warnings and precautions associated with LOPRESSOR.
• Worsening angina or myocardial infarction
• Worsening heart failure
• Worsening AV block
See Full Prescribing Information for additional adverse reactions associated with LOPRESSOR.
• Catecholamine depleting drugs (e.g., reserpine, MAO inhibitors) can increase the risk of bradycardia or hypotension, which may produce vertigo, syncope, or postural hypotension.
• While taking beta-blockers, patients with a history of severe anaphylactic reactions to various allergens may exhibit increased sensitivity to repeated exposure and may not respond adequately to usual doses of epinephrine used for treating allergic reactions.
• Strong CYP2D6 inhibitors—such as quinidine, fluoxetine, paroxetine, and propafenone—have been shown to double plasma concentrations of metoprolol. Although data on moderate or weak inhibitors are lacking, they may also elevate metoprolol levels. Increased plasma concentrations can reduce the cardioselectivity of metoprolol. If co-administration is unavoidable, patients should be monitored closely.
• Digitalis glycosides, clonidine, diltiazem, and verapamil reduce the heart rate by slowing atrioventricular conduction. When used with beta-blockers, the risk of bradycardia may increase. See Full Prescribing Information for additional potential drug interactions associated with LOPRESSOR.
• If high blood pressure or a heart attack is not treated during pregnancy, it can be harmful to both the mother and baby. Metoprolol can pass through the placenta, so babies born to mothers taking this medication may be at risk for low blood pressure, low blood sugar, a slow heart rate, and trouble breathing. Babies should be closely monitored after birth if the mother took metoprolol during pregnancy.
• No adverse reactions of metoprolol on the breastfed infant have been identified. There is no information regarding the effects of metoprolol on milk production.
• Based on the published literature, metoprolol may cause erectile dysfunction and inhibit sperm motility.
• Pediatric use of LOPRESSOR has not been studied.
• In general, use a low initial starting dose in elderly patients given their greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
• LOPRESSOR has not been studied in patients with hepatic impairment.
• The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. No reduction in dosage is needed in patients with chronic renal failure.
• Overdosage of LOPRESSOR may lead to severe bradycardia, hypotension, and cardiogenic shock. Clinical presentation can also include atrioventricular block, heart failure, bronchospasm, hypoxia, impairment of consciousness/coma, nausea and vomiting.
LOPRESSOR is available as a 10 mg/mL oral solution.
To report SUSPECTED ADVERSE REACTIONS, contact Validus Pharmaceuticals LLC at 1-866-982-5438 or the FDA at www.fda.gov/medwatch
Please see Full Prescribing Information at liquid.lopressor.us.com
LOP 003-25
INDICATIONS AND USAGE
LOPRESSOR is a beta-adrenergic blocker indicated in adult patients
Thank you for your interest in Lopressor® Oral Solution, please fill out the
form below and our representative will reach out to you within 24 hours.
Please fill out the form below and we’ll contact you within 24 hours.